Interstitial lung disease and surfactant dysfunction as a secondary manifestation of disease: insights from lysosomal storage disorders

Q3 Pharmacology, Toxicology and Pharmaceutics
Tamara L. Paget, Emma J. Parkinson-Lawrence, Sandra Orgeig
{"title":"Interstitial lung disease and surfactant dysfunction as a secondary manifestation of disease: insights from lysosomal storage disorders","authors":"Tamara L. Paget,&nbsp;Emma J. Parkinson-Lawrence,&nbsp;Sandra Orgeig","doi":"10.1016/j.ddmod.2019.03.001","DOIUrl":null,"url":null,"abstract":"<div><p>Lysosomal storage<span><span><span> disorders are a group of genetic </span>metabolic disorders<span> caused by dysfunctional endosomal-lysosomal hydrolases, altered vesicular trafficking or biogenesis of the </span></span>lysosome<span>. This results in the accumulation of partially degraded substrates within cells, leading to abnormalities in multiple organ systems and reduced life expectancy. These diseases are chronic and progressive with the more severe cases experiencing the onset of disease symptoms early in life. These symptoms include skeletal, joint, airway and cardiac manifestations. Many of the lysosomal storage disorders exhibit significant respiratory issues, which frequently appear to affect pulmonary surfactant<span><span> metabolism leading to an increased morbidity. Interstitial lung disease (ILD) refers to a group of disorders involving the airspaces and tissue compartments of the lung. The major categories of ILD in children that present in the </span>neonatal period include developmental disorders, growth disorders, pulmonary surfactant dysfunction disorders, and specific conditions of unknown etiology unique to infancy. The purpose of this review is to examine the commonalities between lysosomal storage disorders with respiratory pathology and interstitial lung diseases. Increased awareness of the commonalities may instigate a more thorough investigation of symptoms thus providing an accurate and timely diagnosis enabling more precise treatment that will improve patient wellbeing.</span></span></span></p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2019.03.001","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Disease Models","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740675718300331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 5

Abstract

Lysosomal storage disorders are a group of genetic metabolic disorders caused by dysfunctional endosomal-lysosomal hydrolases, altered vesicular trafficking or biogenesis of the lysosome. This results in the accumulation of partially degraded substrates within cells, leading to abnormalities in multiple organ systems and reduced life expectancy. These diseases are chronic and progressive with the more severe cases experiencing the onset of disease symptoms early in life. These symptoms include skeletal, joint, airway and cardiac manifestations. Many of the lysosomal storage disorders exhibit significant respiratory issues, which frequently appear to affect pulmonary surfactant metabolism leading to an increased morbidity. Interstitial lung disease (ILD) refers to a group of disorders involving the airspaces and tissue compartments of the lung. The major categories of ILD in children that present in the neonatal period include developmental disorders, growth disorders, pulmonary surfactant dysfunction disorders, and specific conditions of unknown etiology unique to infancy. The purpose of this review is to examine the commonalities between lysosomal storage disorders with respiratory pathology and interstitial lung diseases. Increased awareness of the commonalities may instigate a more thorough investigation of symptoms thus providing an accurate and timely diagnosis enabling more precise treatment that will improve patient wellbeing.

Abstract Image

间质性肺病和表面活性物质功能障碍作为疾病的继发性表现:来自溶酶体贮积障碍的见解
溶酶体贮积障碍是一组由内溶酶体水解酶功能失调、囊泡运输或溶酶体生物发生改变引起的遗传代谢障碍。这导致细胞内部分降解底物的积累,导致多器官系统异常和预期寿命缩短。这些疾病是慢性和进行性的,较严重的病例在生命早期出现疾病症状。这些症状包括骨骼、关节、气道和心脏表现。许多溶酶体贮积紊乱表现出明显的呼吸问题,这往往会影响肺表面活性物质代谢,导致发病率增加。间质性肺病(ILD)是指一组涉及肺的空气空间和组织室的疾病。出现在新生儿期的儿童ILD的主要类别包括发育障碍、生长障碍、肺表面活性物质功能障碍和婴儿期特有的病因不明的特殊情况。这篇综述的目的是探讨呼吸病理溶酶体贮积障碍和间质性肺疾病之间的共同点。提高对这些共性的认识可能会促使对症状进行更彻底的调查,从而提供准确和及时的诊断,从而实现更精确的治疗,从而改善患者的健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Discovery Today: Disease Models
Drug Discovery Today: Disease Models Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
自引率
0.00%
发文量
0
期刊介绍: Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信